APH Stock Overview Acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteAlliance Pharma plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Alliance Pharma Historical stock prices Current Share Price UK£0.61 52 Week High UK£0.61 52 Week Low UK£0.25 Beta 0.62 1 Month Change 31.47% 3 Month Change 33.77% 1 Year Change 65.99% 3 Year Change -44.85% 5 Year Change -29.89% Change since IPO 205.00%
Recent News & Updates An undisclosed funds, managed by DBAY Advisors Limited, An undisclosed funds, managed by Baring Asset Management Limited, Edmond De Rothschild Equity Strategies IV Fund, a fund managed by Edmond de Rothschild Private Equity Management Ltd. and an undisclosed buyer reached an agreement to acquire remaining 72.05% stake in Alliance Pharma plc (AIM:APH) from Andrew Franklin and Richard Jones for approximately £250 million. Jan 12
New major risk - Share price stability Jan 10 An undisclosed funds, managed by DBAY Advisors Limited, An undisclosed funds, managed by Baring Asset Management Limited, Edmond De Rothschild Equity Strategies IV Fund, a fund managed by Edmond de Rothschild Private Equity Management Ltd. reached an agreement to acquire remaining 72.05% stake in Alliance Pharma plc (AIM:APH) from Andrew Franklin and Richard Jones for approximately £250 million. Jan 10
First half 2024 earnings released: EPS: UK£0.009 (vs UK£0.009 in 1H 2023) Oct 01
Alliance Pharma plc to Report First Half, 2024 Results on Sep 30, 2024 Sep 12
Investors Aren't Entirely Convinced By Alliance Pharma plc's (LON:APH) Revenues Sep 10 See more updates An undisclosed funds, managed by DBAY Advisors Limited, An undisclosed funds, managed by Baring Asset Management Limited, Edmond De Rothschild Equity Strategies IV Fund, a fund managed by Edmond de Rothschild Private Equity Management Ltd. and an undisclosed buyer reached an agreement to acquire remaining 72.05% stake in Alliance Pharma plc (AIM:APH) from Andrew Franklin and Richard Jones for approximately £250 million. Jan 12
New major risk - Share price stability Jan 10 An undisclosed funds, managed by DBAY Advisors Limited, An undisclosed funds, managed by Baring Asset Management Limited, Edmond De Rothschild Equity Strategies IV Fund, a fund managed by Edmond de Rothschild Private Equity Management Ltd. reached an agreement to acquire remaining 72.05% stake in Alliance Pharma plc (AIM:APH) from Andrew Franklin and Richard Jones for approximately £250 million. Jan 10
First half 2024 earnings released: EPS: UK£0.009 (vs UK£0.009 in 1H 2023) Oct 01
Alliance Pharma plc to Report First Half, 2024 Results on Sep 30, 2024 Sep 12
Investors Aren't Entirely Convinced By Alliance Pharma plc's (LON:APH) Revenues Sep 10
Alliance Pharma plc Announces Jeyan Heper to Leave the Business as Chief Operating Officer, Effective 31 August 2024 Jul 23
Is Alliance Pharma (LON:APH) A Risky Investment? Jun 21
Alliance Pharma plc, Annual General Meeting, Jul 29, 2024 Jun 20
New minor risk - Financial position Jun 20
Full year 2023 earnings: EPS misses analyst expectations Jun 20
Alliance Pharma plc Provides Preliminary Results for the Year Ended 31 December 2023 Jun 20
Alliance Pharma plc to Report Fiscal Year 2023 Results on Jun 19, 2024 Jun 19
New minor risk - Share price stability Jun 13 Amberen, Brand of Alliance Pharma plc, Announces Launch of Amberen ENERGY MOOD SLEEP Gummies May 31
Alliance Pharma plc Announces CEO Changes May 09
Alliance Pharma plc to Report Fiscal Year 2023 Results on Apr 09, 2024 Mar 04
Not Many Are Piling Into Alliance Pharma plc (LON:APH) Just Yet Feb 23
Alliance Pharma plc Announces Board Changes Feb 05
Price target decreased by 7.9% to UK£0.75 Jan 31
High number of new directors Dec 01
Estimating The Intrinsic Value Of Alliance Pharma plc (LON:APH) Nov 21
Alliance Pharma plc Announces Appointment of Non-Executive Directors Nov 07
Price target decreased by 8.0% to UK£0.84 Sep 28
Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023 Sep 27
Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023 Sep 26
Alliance Pharma plc to Report First Half, 2023 Results on Sep 26, 2023 Aug 10
Upcoming dividend of UK£0.012 per share at 3.1% yield Jun 15
Consensus EPS estimates fall by 13% May 30
We Think Alliance Pharma (LON:APH) Is Taking Some Risk With Its Debt May 26
Consensus EPS estimates fall by 11% May 05
Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models Mar 24
Full year 2022 earnings: EPS misses analyst expectations Mar 21
Price target decreased by 9.1% to UK£0.92 Mar 17 Alliance Pharma plc Appoints Martin Sutherland as Non-Executive Director
Price target decreased to UK£0.97 Jan 17
Alliance Pharma plc to Report Fiscal Year 2022 Final Results on Mar 21, 2023 Jan 17 Alliance Pharma plc Announces Executive Changes
Logistics Development Group plc acquired a 2.38% stake in Alliance Pharma plc for £5.9 million. Dec 24
Consensus EPS estimates fall by 17% Dec 14
Consensus EPS estimates fall by 17% Nov 24 Alliance Pharma plc Announces CEO Changes
We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt Sep 30
First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Sep 21 Alliance Pharma plc Announces Revenue Guidance for Second Half of 2022
Upcoming dividend of UK£0.011 per share Jun 02 Alliance Pharma plc Announces Directorate Changes
Alliance Pharma plc to Report First Half, 2022 Results on Sep 20, 2022 May 12
Alliance Pharma plc, Annual General Meeting, May 18, 2022 Apr 07
Alliance Pharma plc, Annual General Meeting, May 18, 2022 Apr 06
Insufficient new directors Feb 02
Price target increased to UK£1.25 Jan 29
Price target increased to UK£1.20 Jan 18
First half 2021 earnings released: EPS UK£0.015 (vs UK£0.003 loss in 1H 2020) Sep 23
Upcoming dividend of UK£0.011 per share Jun 03
An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued May 28
Alliance Pharma plc Provides Earnings Guidance for the Full Year of 2021 May 19
Independent Non-Executive Director has left the company May 04
Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet Mar 30
Full year 2020 earnings released: EPS UK£0.015 (vs UK£0.048 in FY 2019) Mar 25
Price target lowered to UK£1.11 Feb 18 Alliance Pharma plc, Annual General Meeting, May 19, 2021
Price target raised to UK£1.00 Jan 09
Alliance Pharma plc (AIM:APH) acquired Biogix, Inc. for $110 million. Dec 30
Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%? Dec 24
New 90-day high: UK£0.79 Dec 24
New 90-day high: UK£0.77 Dec 08
Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently? Nov 19
New 90-day high: UK£0.76 Nov 04
Analysts update estimates Sep 29
First half earnings released Sep 23
New 90-day high - UK£0.77 Jul 21
Alliance Pharma plc to Report First Half, 2020 Results on Sep 22, 2020 Jul 21 Shareholder Returns APH GB Pharmaceuticals GB Market 7D -0.2% -1.1% 1.0% 1Y 66.0% -0.8% 9.5%
See full shareholder returns
Return vs Market: APH exceeded the UK Market which returned 9.5% over the past year.
Price Volatility Is APH's price volatile compared to industry and market? APH volatility APH Average Weekly Movement 11.6% Pharmaceuticals Industry Average Movement 6.7% Market Average Movement 4.9% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: APH's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: APH's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Alliance Pharma plc acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.
Show more Alliance Pharma plc Fundamentals Summary How do Alliance Pharma's earnings and revenue compare to its market cap? APH fundamental statistics Market cap UK£330.29m Earnings (TTM ) -UK£33.58m Revenue (TTM ) UK£183.15m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) APH income statement (TTM ) Revenue UK£183.15m Cost of Revenue UK£74.33m Gross Profit UK£108.82m Other Expenses UK£142.40m Earnings -UK£33.58m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.062 Gross Margin 59.42% Net Profit Margin -18.34% Debt/Equity Ratio 46.0%
How did APH perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/17 18:34 End of Day Share Price 2025/01/17 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Alliance Pharma plc is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Samuel England Berenberg Julie Simmonds Canaccord Genuity Mark Brewer Cavendish
Show 13 more analysts